VI
Vir Bio
VIR·NASDAQSan Francisco CAFounded 2016500 employees
Small CapbiotechPublicInfectious DiseaseOncology
Platform: T-cell & Ab Eng
Market Cap
$1.2B
All Drugs
2
Clinical Trials
2
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (VIR)
Loading VIR stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Voxazasiran | VIR-7248 | Phase 2/3 | 1 | JAK2 | ThymomaUC | ||
| VIR-5526 | VIR-5526 | Phase 3 | 1 | KRASG12C | HNSCC |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (3)